Search

Displaying results 2701 - 2710 of 4859 in total
  1. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On ...

  2. Drug

    Elenestinib

    go.drugbank.com/drugs/DB18489
    Investigational

    Elenestinib is a selective KIT inhibitor.

  3. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. … [L13290] It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.

  4. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    It has also been withdrawn from the Canadian market.[A669,L43942]

  5. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    It is not effective against Enterococcus faecalis infections.

  6. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  7. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  8. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility

  9. Drug

    Farabursen

    go.drugbank.com/drugs/DB18127
    Investigational

    RGLS-8429 is an investigational anti-miR-17 oligonucleotide.

  10. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    It was being codeveloped by Shionogi and GlaxoSmithKline.